Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGX1321 in Advanced Solid and GI Tumors
NCT02675946Phase 1Unknown
- Sponsor
- Curegenix
- Start
- Feb 2016
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of CGX1321 in solid tumor, gastrointestinal cancer and colorectal cancer (CRC) (3 arms), sponsored by Curegenix. Primary endpoint: Number of participants with adverse events and/or abnormal laboratory values that are related to treatment at 55 months. Status: unknown.
02
Drugs
CGX1321
03
Conditions
solid tumorgastrointestinal cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02675946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02675946.